nimesulide has been researched along with Cholera Infantum in 5 studies
nimesulide: structure
nimesulide : An aromatic ether having phenyl and 2-methylsulfonamido-5-nitrophenyl as the two aryl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nimesulide had lower visual analogue scores (VAS) for haemorrhage and erosive lesions in the stomach (p<0." | 2.70 | Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen. ( Barry, M; Bjarnason, I; Fitzgerald, DJ; Gudjonsson, H; Kay, E; Murray, FE; Oddsson, E; Price, AB; Shah, AA; Sigthorsson, G; Thjodleifsson, B, 2001) |
| "Nimesulide was in the low-medium range of RR." | 1.39 | Risk of upper gastrointestinal complications in a cohort of users of nimesulide and other nonsteroidal anti-inflammatory drugs in Friuli Venezia Giulia, Italy. ( Barbone, F; Castellsague, J; Clagnan, E; Drigo, D; Giangreco, M; Perez-Gutthann, S; Pisa, F; Riera-Guardia, N; Rosolen, V; Tosolini, F; Zanier, L, 2013) |
| " Chronic administration of NSAIDs at the ED(50) doses (nimesulide, rofecoxib and naproxen for 15 days) significantly reversed the age or scopolamine-induced retention deficits in both test paradigms." | 1.31 | Modulatory role of cyclooxygenase inhibitors in aging- and scopolamine or lipopolysaccharide-induced cognitive dysfunction in mice. ( Jain, NK; Kulkarni, SK; Patil, CS; Singh, A, 2002) |
| " This is due to the lower incidence of gastrointestinal adverse events with nimesulide, and the absence of serious gastrointestinal complications leading to hospitalization, which more than offset the higher acquisition cost of nimesulide." | 1.30 | Economic comparison of nimesulide and diclofenac, and the incidence of adverse events in the treatment of rheumatic disease in Greece. ( Liaropoulos, L, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Castellsague, J | 1 |
| Pisa, F | 1 |
| Rosolen, V | 1 |
| Drigo, D | 1 |
| Riera-Guardia, N | 1 |
| Giangreco, M | 1 |
| Clagnan, E | 1 |
| Tosolini, F | 1 |
| Zanier, L | 1 |
| Barbone, F | 1 |
| Perez-Gutthann, S | 1 |
| Jain, NK | 1 |
| Patil, CS | 1 |
| Kulkarni, SK | 1 |
| Singh, A | 1 |
| de Leval, X | 1 |
| Julémont, F | 1 |
| Benoit, V | 1 |
| Frederich, M | 1 |
| Pirotte, B | 1 |
| Dogné, JM | 1 |
| Liaropoulos, L | 1 |
| Shah, AA | 1 |
| Thjodleifsson, B | 1 |
| Murray, FE | 1 |
| Kay, E | 1 |
| Barry, M | 1 |
| Sigthorsson, G | 1 |
| Gudjonsson, H | 1 |
| Oddsson, E | 1 |
| Price, AB | 1 |
| Fitzgerald, DJ | 1 |
| Bjarnason, I | 1 |
1 review available for nimesulide and Cholera Infantum
| Article | Year |
|---|---|
First and second generations of COX-2 selective inhibitors.
Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etoricoxib; Gas | 2004 |
1 trial available for nimesulide and Cholera Infantum
| Article | Year |
|---|---|
Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen.
Topics: Adolescent; Adult; Aged; Biomarkers; Cross-Over Studies; Cyclooxygenase Inhibitors; Double-Blind Met | 2001 |
3 other studies available for nimesulide and Cholera Infantum
| Article | Year |
|---|---|
Risk of upper gastrointestinal complications in a cohort of users of nimesulide and other nonsteroidal anti-inflammatory drugs in Friuli Venezia Giulia, Italy.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Cohor | 2013 |
Modulatory role of cyclooxygenase inhibitors in aging- and scopolamine or lipopolysaccharide-induced cognitive dysfunction in mice.
Topics: Aging; Animals; Anxiety; Avoidance Learning; Cognition Disorders; Cyclooxygenase 1; Cyclooxygenase 2 | 2002 |
Economic comparison of nimesulide and diclofenac, and the incidence of adverse events in the treatment of rheumatic disease in Greece.
Topics: Ambulatory Care; Anti-Inflammatory Agents, Non-Steroidal; Cost-Benefit Analysis; Cyclooxygenase Inhi | 1999 |